EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
The preclinical biotech startup, EraCal Therapeutics, which develops drugs using cutting-edge science to treat health and obesity issues, has joined the SFNV.
Switzerland, February 2021 – EraCal Therapeutics, a Swiss producer of biotechnology drugs using cutting-edge technology to treat metabolic syndrome, has joined the SFNV. The company is currently focusing on a pipeline of appetite suppressants to tackle obesity and its metabolic complications. Its lead molecule, Era-107, is an oral appetite suppressor with superior efficacy and safety profile, as demonstrated in three vertebrate species. EraCal is now preparing to carry out further toxicology studies ahead of first-in-human trials.
For more information:
E-mail : info@eracal.ch
Latest Members
New SFNV Steering Committee member Dr. Ian Roberts on innovation and collaboration in sustainable food systems
Collaboration, technology, and...
Alessandre Keller joins the SFNV Steering Committee to drive innovation across health, nutrition and food
The future of health will increasingly...
Pasta Premium launches cook-stable pasta without egg white using EggField Aquafaba
In collaboration with EggField, Pasta...